

A microscopic image of prostate cancer cells, showing a large, textured, orange-brown mass in the foreground with several thin, branching structures extending from it. The background is a soft, out-of-focus yellow and white. A curved purple and pink gradient bar is at the top right and bottom left of the page.

INVITATION

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Case Sharing based on the AUA Index Patients

Saturday, 18 October 2014 • 12:00–16:00

The Shanghai Room, Level 8
The Langham Place Hotel
Mong Kok, Kowloon

Dear Doctor,

We are pleased to invite you to the **Metastatic Castration-Resistant Prostate Cancer (mCRPC) Case Sharing based on the AUA Index Patients.**

The last decade has witnessed a remarkable expansion in the number of therapeutic agents for mCRPC. Nevertheless, these advances have made treatment decisions increasingly complex and challenging. This is further compounded by the heterogeneity of the disease and the lack of clinical data informing the optimal treatment sequencing for these agents.

The meeting presents a unique opportunity for both urologists and oncologists to participate in an event dedicated to bridging the gap between best evidence and best practice in mCRPC management. In this case-centric program, expert faculty will highlight effective treatment-sequencing strategies and multidisciplinary approaches to care of patients with mCRPC. Discussions will focus on key clinical data, guideline recommendations and the relative advantages and disadvantages of treatment choices in specific patient types.

In closing, we are confident that you will find this interactive meeting stimulating and worthwhile.

Program

Co-chairs: Dr William Foo (Hong Kong) & Professor Anthony CF Ng (Hong Kong)	
Time	Topic
12:00–12:05	Opening <i>Professor Anthony CF Ng (Hong Kong)</i>
12:05–13:20	Sequencing of current novel pharmacotherapy for mCRPC <i>Associate Professor Declan Murphy (Australia)</i>
13:20–13:40	AUA index patient 2 (mCRPC, pre-chemotherapy, asymptomatic or minimally symptomatic) <i>Professor Anthony CF Ng (Hong Kong)</i>
13:40–14:00	AUA index patient 3 (mCRPC, pre-chemotherapy, symptomatic and good performance status) <i>Dr Tam Po Chor (Hong Kong)</i>
14:00–14:20	AUA index patient 4 (mCRPC, pre-chemotherapy, symptomatic and poor performance status) <i>Dr Peggy Chu (Hong Kong)</i>
14:20–14:40	Coffee break
14:40–15:00	AUA index patient 5 (mCRPC, post-chemotherapy, symptomatic and good performance status) <i>Dr Angus Leung (Hong Kong)</i>
15:00–15:20	AUA index patient 6 (mCRPC, post-chemotherapy, symptomatic and poor performance status) <i>Dr Darren Poon (Hong Kong)</i>
15:20–15:50	Multidisciplinary approach to prostate cancer treatment <i>Professor CF Anthony Ng (Hong Kong) & Dr Darren Poon (Hong Kong)</i>
15:50–16:00	Closing <i>Dr William Foo (Hong Kong)</i>

Note: Working lunch will be provided upon arrival.



International Invited Speaker

Associate Professor Declan Murphy
The Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia

Declan Murphy is Consultant Urological Surgeon and Director of Robotic Surgery at the Peter MacCallum Cancer Centre in Melbourne, Australia. Concurrently, he is also Consultant Urological Surgeon at Royal Melbourne Hospital, Director of Outcomes Research at the Australian Prostate Cancer Research Centre, and Honorary Clinical Associate Professor at the Department of Surgery, University of Melbourne, St Vincent's Hospital, all in Melbourne.

Dr Murphy is trained in all aspects of open and endoscopic urology, with interest centered on laparoscopic and robotic-assisted surgery, particularly for the management of prostate, renal and bladder cancer. He was awarded his FRCS in Urology in 2006, and his FRACS in Urology in 2011.

Dr Murphy has published extensively in the field of minimally invasive urology for the management of prostate, renal and bladder cancer. He is Associate Editor of *BJU International*, Consulting Editor of *European Urology*, and serves on the expert advisory board for *Nature Reviews Urology* and the editorial board of the *Journal of Robotic Surgery*. Furthermore, he is a regular reviewer for the *Journal of Urology*, *Journal of Endourology*, *Journal of Sexual Medicine*, and *Cancer*, among others.

Since 2010, Dr Murphy has convened the Urology program at the Asia-Pacific Prostate Cancer Conference, one of the world's leading prostate cancer educational events.

Chairs and Speakers

Professor Anthony CF Ng Professor Faculty of Medicine The Chinese University of Hong Kong	Dr Peggy Chu Consultant Department of Urology Tuen Mun Hospital	Dr Darren Poon Associate Consultant Department of Clinical Oncology Prince of Wales Hospital
Dr Tam Po Chor Consultant Hong Kong Urology Clinic	Dr Angus Leung Consultant Radiotherapy & Oncology Centre Baptist Hospital	Dr William Foo Director Radiotherapy & Oncology Centre Baptist Hospital

REPLY SLIP

Name: _____

Address: _____

Contact number: _____ Email: _____

Important notes:

1. For reservation, please complete and fax a copy of this slip to 2736 1926 or e-mail it to sleung4@its.jnj.com.
2. CME credits are pending approval by the College of Surgeons of Hong Kong and the Hong Kong College of Radiologists.
3. For more information or inquiries, please contact Ms Samantha Leung at 2738 6149.



Hong Kong Society of Clinical Oncology



香港泌尿外科學會
Hong Kong Urological Association

Supported by an independent educational grant from



Unit 1302-1307, Tower 1, Grand Century Place,
193 Prince Edward Road West, Mongkok, Kowloon, Hong Kong
Tel: 2736 1711 Fax: 2736 1926